News & Events

Immuno-Oncology Summit 2017 ta-Scan analysis

Get your FREE Immuno-Oncology Therapy Analysis by ta-Scan

Today brings the start of the Immuno-Oncology Summit 2017 in Boston, supporting researchers in developing the next generation of immunotherapies. Immuno-oncology researchers are changing the way we treat cancer by unleashing the immune system and achieving functional cures in some cancers.

MDCPartners and its ta-Scan team contribute to this purpose by teaching how clinical planners can leverage our clinical businesses intelligence software and our data merging services to get to their answers faster. The ta-Scan team created a useful analysis on oncolytic virus therapies in clinical trials. We thought today would be a good occasion to share this report with you.

>>> Click here to download the analysis <<<

Share on:
Tweet about this on TwitterShare on LinkedIn
ta-Scan and MDCPartners at Immuno-Oncology Summit 2017 Boston

Connect with MDCPartners at the Immuno-Oncology Summit 2017

Connect with MDCPartners at Immuno-Oncology Summit 2017 from August 28 to September 1, 2017 in Boston, MA. Visit MDCPartners at booth #32 to discover next generation targeted immunotherapies and find new ways to navigate clinical data and overlap internal data with MDCPartners’ public data cloud.

Join us in Boston

Would you like to know how our clinical business intelligence software ta-Scan or our other data solutions can help with your company’s data challenges? Then feel free to pop by booth #32 or make an appointment with MDCPartners’ Director of Business Development, North America Matt Tumasz and/or Strategic Analyst, Oncology, Dr. Jonathan Crowther. They will gladly show you our state of the art tools.

Register Today

Secure your place now if you want to connect with the ta-Scan team in Boston. MDCPartners has arranged for an exclusive discount on CHI’s Immuno-Oncology Summit. Use promo code MDC when registering to receive your $200 registration discount. This discount applies to conference programs only and cannot be used on short courses, combined with other offers, or transferred.

How to register:
Online: https://chidb.com/reg/imx/reg.asp
By Phone: +1 781-972-5472

Immuno-Oncology Summit 2017 Program

Now in its fifth year, the Immuno-Oncology Summit will return to Boston again this August 28-September 1 with the goal of supporting researchers in developing the next generation of immunotherapies. Immuno-oncology researchers are changing the way we treat cancer by unleashing the immune system and achieving functional cures in some cancers.

This year’s IO Summit has been designed to give attendees a complete picture of the field and its advances with 12 conference tracks, 1 in-depth training seminar, and 4 instructional short courses. Topics include immunotherapy discovery, development, biomarkers, and translational oncology as well as emerging topic areas such as cancer vaccines, oncolytic viruses, and advances in synthetic biology techniques. Overall, this event provides a focused look at how researchers are applying new science and technology in the development of effective and safe immunotherapies.

Download the digital brochure for full details.

We look forward to seeing you in Boston!

Share on:
Tweet about this on TwitterShare on LinkedIn
DIA 2017 ta-Scan mobile app David Cocker

Meet David Cocker at DIA 2017 and discover the new ta-Scan mobile app!

MDCPartners’ CSO David Cocker will be attending the DIA 2017 meeting in Chicago on June 18-22 to showcase ta-Scan‘s new mobile app.

About DIA 2017

The Drug Information Association, a non-profit association, is the only global organization dedicated to bringing health care product development professionals together in a trusted, global, neutral environment to share insights and drive action in health care product development and life cycle management.

ta-Scan Mobile App

ta-Scan now has its own mobile app! Have a look at the video below: it’s a little demo on how it works. This tool enables MSLs to search for high ranking investigators on the go. Clinical business intelligence is now truly at your fingertips.

Meet us in Chicago

Book an appointment now to connect with David Cocker in Chicago.

We look forward to seeing you in Chicago!

Share on:
Tweet about this on TwitterShare on LinkedIn
ASCO 2017 ta-scan analysis

Curious about what to expect at ASCO 2017? ta-Scan has you covered!

As ASCO 2017 kicks off this Friday, finding the information relevant to you can be a hassle. Using ta-Scan, you can quickly uncover key information about sponsors, clinical trials, drugs and investigators contributing to ASCO this year. To help you out, we highlight a few interesting points.

asco 2017 abstracts

Abstracts

Over the past 3 years, there have been some notable changes in therapeutic areas discussed at the American Society of Clinical Oncology’s annual meeting. It comes as no surprise that the Immune Oncology trend is growing year on year, much like Lung Cancer. On the other hand, interest in Breast Cancer is steadily declining, which could be due to the disappointing results of Immune Oncology within Breast Cancer. Another interesting fact is the gain in Gastrointestinal Cancer abstracts at this year’s conference, after a relatively quiet 2016.

asco 2017 abstracts ta distribution

Sponsor & trial activity

Of the 1,203 clinical trials that are cited at ASCO 2017, 6 key commercial sponsors have seen considerable fluctuations in trial activity when compared to ASCO 2016. Significant gains can be seen in the trial activity of BMS, Pfizer, and Roche, whereas Novartis, Sanofi, and Johnson & Johnson have seen a decrease in trial numbers.

asco 2017 abstracts ta distribution

ta-Scan’s top 5 drugs to watch at ASCO 2017

With preliminary results already disclosed for some drugs debuting at ASCO, ta-Scan highlights some new drugs being discussed in the Immune Oncology space. Introduction of two Antibody drug conjugates for Prostate and Breast Cancer, the Colony Stimulating Factor-1 receptor Cabiralizumab and CD122 compounds from Nektar that facilitate immune response against tumors. In addition to anti-PD-L1 compound Incyte have a promising combination with Pembrolizumab and an indolamine 2,3 dioxygenase inhibitor, Epacadostat.

asco 2017 abstracts pd-pd-l

Investigator & sponsor collaborations

Looking at the percentage of top Oncology experts used by the leading commercial sponsors of trials talked about at ASCO 2017, it’s clear that Roche and Merck have an evenly distributed usage of investigators in both the USA as well as Europe, whereas others seem to lean toward USA investigator preference.

asco 2017 abstracts top oncology investigators

ta-Scan’s top 5 drugs to watch at ASCO 2017

With preliminary results already disclosed for some drugs debuting at ASCO, ta-Scan highlights some new drugs being discussed in the Immune Oncology space. Introduction of two Antibody drug conjugates for Prostate and Breast Cancer, the Colony Stimulating Factor-1 receptor Cabiralizumab and CD122 compounds from Nektar that facilitate immune response against tumors. In addition to anti-PD-L1 compound Incyte have a promising combination with Pembrolizumab and an indolamine 2,3 dioxygenase inhibitor, Epacadostat.

asco 2017 abstracts new drugs

Learn more about ta-Scan

Interested in ta-Scan‘s analytical services? Request your free webinar here or contact us.

Share on:
Tweet about this on TwitterShare on LinkedIn
MDCPartners' founder and CEO, Mireille De Cré, explains how pharma R&D can make the most of the big data revolution in the European Pharmaceutical Manufacturer Magazine.

BIG Data: How Pharma Can Use it to its Advantage

In this European Pharmaceutical Manufacturer Magazine opinion article, MDCPartners’ founder and CEO, Mireille De Cré, explains how pharma R&D can make the most of the big data revolution.

The big data hype train has been gaining momentum for a number of years and its rise has been well documented. However, pharma companies are still perplexed by the scope of what big data can do, and why, how and where they should use big data tools to their advantage.

With focus moving away from sheer volume of data and inherent variability and complexity of large unstructured datasets towards user-friendly analytic tools that can help businesses plan for the future, now is the time for big, small and medium size pharma to seize the ‘big data’ opportunity.

What is clear is that big data is here to stay and will continue to have a growing influence in terms of its impact to business decision making across a number of sectors. Some of those in pharma are firmly grasping the opportunity that analytics-based decision making can bring… And those that aren’t will need to catch up before they lose out.

Read more in the European Pharmaceutical Manufacturer Magazine article: http://www.epmmagazine.com/opinion/big-data/

Share on:
Tweet about this on TwitterShare on LinkedIn
CTCLS ta-Scan distributorship Japan

CTCLS Provides Japan with Solution to Support and Accelerate Clinical Development

We are proud to present our partnership with CTC (an ITOCHU Techno-Solutions Corporation division), who will distribute clinical development solution ta-Scan throughout Japan. Headquartered in Tokyo, CTC offers ICT solutions for the life science industries, including the pharmaceutical industry.

For the first time in Japan, CTC has established an agency agreement with MDCPartners, headquartered in Belgium. CTC now distributes ta-Scan, a business intelligence software platform to assist the clinical study program implementation.

“With offering ta-Scan,” CTC states, “it is our objective […] to help reduce clinical study periods and lowering costs in clinical research and development for pharma drug, contributing to the optimization of our customer’s investment and the enhancement of competitiveness.”

For more information and use cases, read CTC’s complete press release.

CTC Contact Information

CTC
Sales Department 2
ls-marcom@ctc-g.co.jp

Share on:
Tweet about this on TwitterShare on LinkedIn
ta-Scan and MDCPartners at Clinical Trial Innovation Summit Boston 2017

Join MDCPartners at Clinical Trial Innovation Summit 2017

CHI’s 6th Annual Clinical Trial Innovation Summit brings together more than 250 leaders from across pharma, biotech and academia to share case studies and best practices on effective clinical trial management and vendor oversight. Of course MDCPartners’ ta-Scan team will be there too. The summit features 6 co-located conferences and 3 dinner short courses. Multiple registration options are available. Download the digital brochure for all details.

2017 Program Highlights

The 2017 Clinical Trial Innovation Summit program focuses on key issues and opportunities in the clinical trial industry, including patient recruitment, site selection, data integration, existing data sources, mobile tech, project management, outsourcing, vendor management, budgeting and contracting, quality (QbD) in trial conduct, risk-based monitoring and clinical auditing.

  • ICH E6 guidance, including gap analysis, action plans, and project plans from clinical trial quality and risk management expert Andy Lawton
  • An assessment of current and future trial technologies: social media, search engine optimization, targeted digital advertising, artificial intelligence and virtual reality
  • Real examples of big data analytics in clinical trials from Takeda, Bayer, Janssen, and BMS
  • Proven strategies for determining timelines, key activity needs, and effective communication for clinical trial outsourcing
  • Case studies from AbbVie, Merck, and Samumed on new methods of risk mitigation, issue management, and oversight plans to ensure quality clinical trials
  • How to navigate regulation and data quality and quantity challenges of wearables, sensors and mHealth from pharma teams in the trenches
  • Lessons learned from AstraZeneca, BMS, Gilead, and several others at the frontline of RBM roll-out

Join us in Boston

Would you like to know how we can help with your company’s data challenges, using our clinical business intelligence software ta-Scan and our other data solutions? Then feel free to pop by at Booth #3 in the exhibition hall (Essex North / Center Ballroom) or make an appointment with MDCPartners Chief Scientific Officer David Cocker or Director of Business Development, North America Matt Tumasz. They will gladly show you our state of the art software tools.

Register Today

Use our discount code MDPCTL for $200 off your registration cost.*

How to Register:
Online: https://chidb.com/reg/ctl/reg.asp
By telephone: +1 781-972-5400

We hope to see you in Boston!

* Our clients and colleagues will receive $200 off for commercial attendees or $100 off for academic, government and hospital-affiliated attendees. You must mention priority keycode MDPCTL to receive the registration discount. Alumni, Twitter, LinkedIn, Facebook or any other promotional discounts cannot be combined. Discounts not applicable on event short courses. This discount does not apply to previously registered attendees.
Share on:
Tweet about this on TwitterShare on LinkedIn
MDCPartners Patient Recruitment Retention Summit 2017 London

Presenting at the Patient Recruitment and Retention Summit in London, 21-23 February 2017

Our next meeting will happen in London this month: MDCPartners will present at the 9th Annual Patient Recruitment and Retention Summit 2017, which will take place in the London Marriott Hotel Kensington during 21-23 February 2017. Hot topics during this meeting:

  • What role does clinical research have on patients?
  • How to make trials more valuable for patients?
  • New regulations and the impact on clinical trials
  • Developing a robust clinical trial recruitment and retention strategy
  • What makes a good feasibility process?
  • How to keep the site staff motivated and engaged?

Click here to request the full event agenda.

Utilizing Big Data to Enhance Patient Recruitment

On Wednesday 22 February 2017 at 11:45 AM MDCPartners’ Strategic Analyst in Oncology, Dr Jonathan Crowther, will talk about:

Utilizing big data to enhance patient recruitment: Analyzing public information for trial feasibility and site selection

The path to clinical trial success is burdened with underperforming site selection, poor patient recruitment and frequent delays. Such barriers result in failures to meet targets and dwindling statistical significance. Comprehensive planning via a feasibility survey can alleviate these issues however, it has been suggested that the accuracy of a survey may be below 10%. As big data becomes more applicable in the clinical trial setting, capitalizing on the wealth of publicly available clinical data is essential. The clinical business intelligence platform ta-Scan semantically links trial, investigator and site information to provide a robust feasibility analysis to help address the following questions:

  • Estimation of appropriate patient cohorts
  • Key Opinion Leaders in the field
  • Competing and historic trials across the therapeutic area
  • Suitable geographic setting for a trial
  • IRB and timing issues that may affect trial start-up

Join us in London

Would you like to join us in London this month to learn more about how to leverage big data for patient recruitment or to see how our real-world data evidence solutions can help with clinical trial planning challenges? Let us know to arrange a meeting with our Technical Product Manager Kristof Geentjens and our Strategic Analyst in Oncology Dr Jonathan Crowther. Or just pop by at booth #5!

Share on:
Tweet about this on TwitterShare on LinkedIn

NEWS RELEASE: MDCPartners launches new ta-Scan software that ‘will revolutionize’ the way pharmaceutical companies plan for the future

Antwerp, Belgium | 24 January 2017 – MDCPartners today launches ta-Scan 5, an update of its global web-based platform that analyses clinical trial data. The new platform is set to revolutionize the way pharmaceutical researchers plan for the future, by providing unrivaled insights that will help inform future business decisions.

The new ta-Scan 5 is the first software of its kind to use exceptionally powerful algorithms to analyse clinical data from multiple global public sources in its patented Trial Cloud®. The new version 5 will mean that pharmaceutical companies are able to obtain more valuable insights on clinical research than ever before, via a more streamlined process.

The software will allow companies to go into more detail on clinical trial research than ever before, with access to over 250,000 clinical trials and 7 million scientific and clinical experts. This will provide unique insights on specific compounds, research institutes, clinical centers, patient populations, key investigators and competitor analysis to help strategic decision making.

“We believe the opportunity in clinical business intelligence is the freedom to look at data from multiple sources, from any region, combined into one system that’s easy to use. The new ta-Scan 5 does just that – it taps into vast amounts of information and provides comprehensive analysis that can be broken down easily. Pharmaceutical companies are now starting to realize their opportunities in gathering the most valuable business intelligence, and I believe the ability of this software will fundamentally change the way clinical research is planned and executed across the industry,” comments David Cocker, CSO for MDCPartners, who is presenting this week at the SCOPE Summit in Miami, Florida.

“For the first time ever, MDCPartners has been able to simplify complex trial-related queries and perform deep analysis using the most powerful algorithms yet. Using Real World Solutions, we can link internal and external information together through a portal, to generate a comprehensive landscape and get a full view of where the competing trials are conducted, and where the patient populations are. Before, we couldn’t link this information, now it is at our fingertips,” comments Dr Bart Naudts, Lead Data Architect at MDCPartners.

The ta-Scan web platform has been used by pharmaceutical and biotech researchers for the last decade. It has transformed and advanced the process of intelligence gathering and analyzes across the industry.

Media Enquiries

MDCPartners
Mireille De Cré
mireille.decre@mdcpartners.be
+32 (0) 3 870 97 50

Tonic Life Communications
Stan Jackson / Chrissie Hannah
stan.jackson@toniclc.com / chrissie.hannah@toniclc.com
+44 (0) 774 771 8279 / +44 (0)777 253 4646

***ENDS***

Notes to Editors

About ta-Scan

ta-Scan is an intelligence web platform for clinical development, which analyses data for trial planning, expert profiling, disease landscape and competitive intelligence, for researchers in the pharmaceutical and biotech industry. It was launched nearly a decade ago to transform and advance the intelligence gathering and analyses that enable clinical development.

Powerful algorithms enable researchers to bypass print publications, restrictive registries and dense databases for the insights they need to make evidence-based decisions. With ta-Scan, users can locate key opinion leader (KOL) associations, investigators with specific therapeutic experience, or institutes with the capacity to conduct complex protocols.

To find out more about ta-Scan, please visit: www.ta-scan.com/product

About ta-Scan 5

ta-Scan 5 is the updated model of ta-Scan, which was recently launched by MDCPartners at the SCOPE Summit in Miami, Florida, in January 2017. It offers a uniquely streamlined and simplified intelligence gathering process and improves data access and value, allowing for a more intuitive, business-oriented workflow.

ta-Scan 5 features a refined and robust search engine tool which activates alternative information pathways with the flexibility to adjust query filters with ease. The number and potential combination of trial-related queries is unrestricted, meaning that hundreds of data classes are semantically connected that can be accessed by one query.

To find out  more about ta-Scan 5, please visit: https://vimeo.com/mdcp/ta-scan5

About MDCPartners

Founded in 1999, MDCPartners specialises in business intelligence and strategic consultancy for the pharmaceutical and biotech industry. They combine drug development expertise with the latest data sciences to provide clinical trial optimisation, medical expert identification and competitive intelligence.

MDCPartners is a leader in the field of data mining and semantic processing. With their patented data solutions, their clients transform millions of dispersed data points into meaningful intelligences.

MDCPartners is headquartered in Antwerp, Belgium, with sales offices in the USA and Japan. It has three flagship products for global pharmaceutical data solutions, including:

  • ta-Scan: the flagship product ta-Scan is a web business intelligence platform that analyses clinical development programmes, trial and site data, and involvement of medical experts
  • normScan: the medical device standards monitoring tool, normScan, is tailored to the client’s medical device portfolio. normScan tracks all relevant device standards and regulatory documents that have been published or are in development
  • Real World Solutions: an evolving area of business for MDCPartners are the customised data solutions, which tap into a robust inventory of algorithms and unique visualisation tools. Users can gain optimal insights from data either as stand-alone or combined with public data

To find out more about MDCPartners, please visit: www.mdcpartners.be

Share on:
Tweet about this on TwitterShare on LinkedIn
MDCPartners ta-Scan 5 SCOPE 2017 Miami Florida

Discover ta-Scan 5 at SCOPE 2017

Summit for Clinical Operations Executives

It’s never too early for good Year’s resolutions! Ours? Start off 2017 with a bang! Indeed, in January 2017, MDCPartners will travel to sunny Florida again for the yearly Summit for Clinical Operations Executives (SCOPE), and it goes without saying that we are already looking forward to it.

The 8th Annual SCOPE Summit, taking place January 24-26, 2017 in Miami, Florida in the Hyatt Regency, will offer three stimulating days of in-depth discussions in 13 different conferences, 6 pre-conference workshops and 2 symposia focused on issues related to each aspect of clinical trial planning and management: Data Integration, Feasibility, Site Selection and Management, Patient Engagement, Recruitment and Retention, Mobile Tech, Project Management, Outsourcing, Forecasting, Budgeting and Contracting, Quality (QbD) in Trial Conduct, Risk-Based Monitoring, Post-Marketing Studies, Observational Research, Clinical Lab Services, Precision Medicine and Biomarker-Driven Trials. View SCOPE’s programs here.

Introducing ta-Scan 5

ta-scan 5 scope 2017

Our business and IT teams will present the clinops experts at SCOPE ta-Scan‘s latest version we have been working on the last months: ta-Scan 5! This update includes a lot of new features and a complete style make-over to enhance the user experience. Join us in Miami to discover how our clinical business intelligence software and our public-private data integration skills can leverage today’s clinical big data challenges.

Meeting Up

ta-Scan team at SCOPE 2017 Miami FloridaIf you want to get an exclusive preview of ta-Scan 5 and learn more about our software solutions, visit us at booth #702 or make an appointment with the team (from left to right, from top to bottom):

  • Bart Naudts, IT Partner
  • David Cocker, CSO
  • Mireille De Cré, CEO
  • Piet van Remortel, IT Partner
  • Matt Tumasz, Director of Business Development USA
  • Jonathan Crowther, Ph.D., Strategic Analyst Oncology
  • Alexandra Moens, Marketing Associate
  • Kristof Geentjens, Technical Product Manager

 

Share on:
Tweet about this on TwitterShare on LinkedIn

Top of Page